---
layout: post
title: "八大券商主题策略：关注四条主线！调整充分、估值较低的医药标的名单来了"
date: 2022-02-25 11:18:29 +0800
categories: emnews
tags: 东财滚动新闻
---
> 国盛证券表示，医药已经进入中长期的布局区间，中短期仍然是自下而上，更重“业绩估值筹码”三因素。医药调整到现在，“双高问题”得到了一定消化，虽然有很多资产短期估值难言极度便宜且短期担忧难以证伪，但从中长期来看已经进入到了配置区间。

<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/90.BK1041" data-code="BK1041|90|1" data-code2="BK1041|90|2|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=90.BK1041&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 BK1041_0" data-code="K BK1041|90|1" data-code2="K BK1041|90|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/90.BK0465" data-code="BK0465|90|1" data-code2="BK0465|90|2|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=90.BK0465&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 BK0465_0" data-code="K BK0465|90|1" data-code2="K BK0465|90|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/90.BK1060" data-code="BK1060|90|1" data-code2="BK1060|90|3|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=90.BK1060&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 BK1060_0" data-code="K BK1060|90|1" data-code2="K BK1060|90|3|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>每日主题策略讨论，<span id="stock_0.300059"><a href="http://quote.eastmoney.com/unify/r/0.300059" class="keytip" data-code="0,300059">东方财富</a></span><span id="quote_0.300059"></span>网汇总八大<span id="Info.3306"><a href="http://data.eastmoney.com/other/qsjy.html" class="infokey">券商</a></span>观点，揭秘行业现状，观察行情走势，提前为您把脉A股。<br /></p><center><img src="https://dfscdn.dfcfw.com/download/D25118255147445558969_w626h638.jpg" width="580" emheight="591" orginial_src="https://dfscdn.dfcfw.com/download/D25118255147445558969_w626h638_o.jpg" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p><strong>平安<span id="bk_90.BK0473"><a href="http://quote.eastmoney.com/unify/r/90.BK0473" class="keytip" data-code="90,BK0473">证券</a></span><span id="bkquote_90.BK0473"></span>：关注四条主线！调整充分、估值较低的医药标的值得重点关注</strong></p><p>主线一：创<span id="stock_0.300832"><a href="http://quote.eastmoney.com/unify/r/0.300832" class="keytip" data-code="0,300832">新产业</a></span><span id="quote_0.300832"></span>链，包括创新药(械)和CXO.CDE新政加速国内创新“新生态”进化，行业面临“再分化”，关注具备临床导向创新能力及license-out能力的公司，建议关注：<span id="stock_1.600276"><a href="http://quote.eastmoney.com/unify/r/1.600276" class="keytip" data-code="1,600276">恒瑞医药</a></span><span id="quote_1.600276"></span>、<span id="Info.116.06160"><a href="http://quote.eastmoney.com/unify/r/116.06160" class="keytip" data-code="116,06160">百济神州</a></span>、<span id="Info.116.01801"><a href="http://quote.eastmoney.com/unify/r/116.01801" class="keytip" data-code="116,01801">信达生物</a></span>、<span id="stock_106.GLW"><a href="http://quote.eastmoney.com/unify/r/106.GLW" class="keytip" data-code="106,GLW">康宁</a></span><span id="quote_106.GLW"></span>杰瑞、<span id="stock_1.688321"><a href="http://quote.eastmoney.com/unify/r/1.688321" class="keytip" data-code="1,688321">微芯生物</a></span><span id="quote_1.688321"></span>。CXO方面，维持高景气度，结合估值以及政策、资金因素，我们更倾向于CDMO和大分子CXO赛道，建议关注：<span id="stock_0.002821"><a href="http://quote.eastmoney.com/unify/r/0.002821" class="keytip" data-code="0,002821">凯莱英</a></span><span id="quote_0.002821"></span>、<span id="stock_0.300363"><a href="http://quote.eastmoney.com/unify/r/0.300363" class="keytip" data-code="0,300363">博腾股份</a></span><span id="quote_0.300363"></span>、<span id="stock_0.300725"><a href="http://quote.eastmoney.com/unify/r/0.300725" class="keytip" data-code="0,300725">药石科技</a></span><span id="quote_0.300725"></span>。</p><p>主线二：产品出海。海外市场是巨大的增量市场，制剂出口有较高门槛，<span id="bk_90.BK1041"><a href="http://quote.eastmoney.com/unify/r/90.BK1041" class="keytip" data-code="90,BK1041">医疗器械</a></span><span id="bkquote_90.BK1041"></span>出海也成为行业新的增长驱动力。建议关注：<span id="stock_1.603707"><a href="http://quote.eastmoney.com/unify/r/1.603707" class="keytip" data-code="1,603707">健友股份</a></span><span id="quote_1.603707"></span>、<span id="stock_0.300630"><a href="http://quote.eastmoney.com/unify/r/0.300630" class="keytip" data-code="0,300630">普利制药</a></span><span id="quote_0.300630"></span>、<span id="stock_0.300760"><a href="http://quote.eastmoney.com/unify/r/0.300760" class="keytip" data-code="0,300760">迈瑞医疗</a></span><span id="quote_0.300760"></span>等。</p><p>主线三：消费型医疗。随着人均可支配收入增长，消费型医疗需求不断提升。同时，消费型医疗均为自费产品，有自主定价权，免疫控费政策。建议关注：<span id="stock_1.600763"><a href="http://quote.eastmoney.com/unify/r/1.600763" class="keytip" data-code="1,600763">通策医疗</a></span><span id="quote_1.600763"></span>、<span id="stock_0.300015"><a href="http://quote.eastmoney.com/unify/r/0.300015" class="keytip" data-code="0,300015">爱尔眼科</a></span><span id="quote_0.300015"></span>、<span id="stock_0.300653"><a href="http://quote.eastmoney.com/unify/r/0.300653" class="keytip" data-code="0,300653">正海生物</a></span><span id="quote_0.300653"></span>等。</p><p>主线四：<span id="bk_90.BK1040"><a href="http://quote.eastmoney.com/unify/r/90.BK1040" class="keytip" data-code="90,BK1040">中药</a></span><span id="bkquote_90.BK1040"></span>板块此前长期处于调整阶段，整体估值较低。板块中<span id="Info.3321"><a href="http://data.eastmoney.com/bbsj/" class="infokey">业绩</a></span>增长稳健的企业性价比高，布局优势凸显。且<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1040" class="em_stock_key_common" data-code="90,BK1040">中药</span>产品出口少，内循环属性明显，因此不会受到国外对华政策的干扰。一些<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1040" class="em_stock_key_common" data-code="90,BK1040">中药</span>产品更加偏向于保健品，消费属性更强，可对标部分食品企业。</p><p>在此前提下，我们认为，调整充分、估值较低的标的值得重点关注。这其中，免疫医保控费政策的OTC药品占比更大、产品有较好的提价空间且中药注射剂占比更小的企业有更大的弹性，建议关注：<span id="stock_1.600285"><a href="http://quote.eastmoney.com/unify/r/1.600285" class="keytip" data-code="1,600285">羚锐制药</a></span><span id="quote_1.600285"></span>、<span id="stock_1.600422"><a href="http://quote.eastmoney.com/unify/r/1.600422" class="keytip" data-code="1,600422">昆药集团</a></span><span id="quote_1.600422"></span>等。在上述几条主线外，还存在一些其他高景气、高壁垒的赛道：包括特色原料药与核医学等。建议关注：<span id="stock_1.603520"><a href="http://quote.eastmoney.com/unify/r/1.603520" class="keytip" data-code="1,603520">司太立</a></span><span id="quote_1.603520"></span>、<span id="stock_0.300497"><a href="http://quote.eastmoney.com/unify/r/0.300497" class="keytip" data-code="0,300497">富祥药业</a></span><span id="quote_0.300497"></span>、<span id="stock_0.300702"><a href="http://quote.eastmoney.com/unify/r/0.300702" class="keytip" data-code="0,300702">天宇股份</a></span><span id="quote_0.300702"></span>、<span id="stock_0.002675"><a href="http://quote.eastmoney.com/unify/r/0.002675" class="keytip" data-code="0,002675">东诚药业</a></span><span id="quote_0.002675"></span>、<span id="Info.116.00512"><a href="http://quote.eastmoney.com/unify/r/116.00512" class="keytip" data-code="116,00512">远大医药</a></span>。<a href="https://dfscdn.dfcfw.com/download/A2_cms_f_20220225112424828692&direct=1&abc1249.pdf">【点击查看研报原文】</a></p><p><strong><span id="stock_1.601375"><a href="http://quote.eastmoney.com/unify/r/1.601375" class="keytip" data-code="1,601375">中原证券</a></span><span id="quote_1.601375"></span>：建议关注新冠药物原料供应商及CRO</strong></p><p>近期欧洲多个国家宣布与新冠病毒共存，“疫苗+新冠药物”仍然是未来抗疫的主要手段，新建议持续关注疫苗和新冠药物领域的投资机会，重点公司包括<span id="stock_0.300122"><a href="http://quote.eastmoney.com/unify/r/0.300122" class="keytip" data-code="0,300122">智飞生物</a></span><span id="quote_0.300122"></span>、<span id="stock_0.300142"><a href="http://quote.eastmoney.com/unify/r/0.300142" class="keytip" data-code="0,300142">沃森生物</a></span><span id="quote_0.300142"></span>、康希诺、<span id="stock_0.300601"><a href="http://quote.eastmoney.com/unify/r/0.300601" class="keytip" data-code="0,300601">康泰生物</a></span><span id="quote_0.300601"></span>、<span id="stock_1.603392"><a href="http://quote.eastmoney.com/unify/r/1.603392" class="keytip" data-code="1,603392">万泰生物</a></span><span id="quote_1.603392"></span>、<span id="Info.116.01877"><a href="http://quote.eastmoney.com/unify/r/116.01877" class="keytip" data-code="116,01877">君实生物</a></span>；随着新冠药物的获批上市，保障原料供应与产能是必备条件，对于新冠药物原料供应相关企业也值得重点关注，如<span id="stock_1.603811"><a href="http://quote.eastmoney.com/unify/r/1.603811" class="keytip" data-code="1,603811">诚意药业</a></span><span id="quote_1.603811"></span>，<span id="stock_0.002001"><a href="http://quote.eastmoney.com/unify/r/0.002001" class="keytip" data-code="0,002001">新和成</a></span><span id="quote_0.002001"></span>、<span id="stock_0.300584"><a href="http://quote.eastmoney.com/unify/r/0.300584" class="keytip" data-code="0,300584">海辰药业</a></span><span id="quote_0.300584"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300497" class="em_stock_key_common" data-code="0,300497">富祥药业</span>；2)创新药发展步入突破性创新阶段，CXO估值调整较多，随着年报的披露，可以继续关注CXO的投资机会，建议重点关注<span id="stock_1.603127"><a href="http://quote.eastmoney.com/unify/r/1.603127" class="keytip" data-code="1,603127">昭衍新药</a></span><span id="quote_1.603127"></span>。<a href="https://dfscdn.dfcfw.com/download/A2_cms_f_20220225112436516337&direct=1&abc8148.pdf">【点击查看研报原文】</a></p><p><strong>长城国瑞<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0473" class="em_stock_key_common" data-code="90,BK0473">证券</span>：估值处于历史底部区域 当前医药行业投资价值凸显</strong></p><p>估值处于历史底部区域，当前行业投资价值凸显，我们建议加大行业的配置比重，关注六个方面的投资机会：一是2021年年报、2022年一季报业绩披露在即，关注年报和一季报业绩有望高增长或超预期的优质标的；二是随着《“十四五”医药工业发展规划》正式发布，在医保控费的大前提下，创新和国际化将是未来行业的核心主线，建议关注创新驱动型公司、具有国际化能力的制药企业；三是CXO行业，CXO行业近期出现深度调整，估值处于历史底部，逆势关注订单充足且当前估值合理的公司；四是目前估值较为合理、企稳回升的药店连锁公司；五是关注消费性医疗版块，在医保控费的大背景下，具有消费属性的眼科、医美等医疗子行业拥有政策免疫性，消费升级将带动其发展；六是关注中药板块，《关于医保支持中医药传承创新发展的指导意见》的发布，表明国家对中医药传承、创新发展的决心，将给中医药行业带来积极的作用。<a href="https://dfscdn.dfcfw.com/download/A2_cms_f_20220225112449391245&direct=1&abc3619.pdf">【点击查看研报原文】</a></p><p><strong><span id="stock_1.600109"><a href="http://quote.eastmoney.com/unify/r/1.600109" class="keytip" data-code="1,600109">国金证券</a></span><span id="quote_1.600109"></span>：CXO板块依旧是医药板块中景气度、持续性、长期逻辑最好的细分方向</strong></p><p>疫情常态化和流感化预期，看好口服新冠药物放量。疫苗、中和抗体和口服新冠药物三管齐下，疫情常态化和流感化预期。基于治疗机制、口服药物的可及性和经济性，我们继续看好口服小分子新冠药物的应用前景。多款国内外口服新冠药物即将进入放量阶段：①原研供应链持续加码供应链供货；②通过MPP平台的权益授予，仿制药企和供应链企业获得仿制药生产和销售权益；③国内新冠口服药布局丰富，研发逐步推进。</p><p>创<span web="1" href="http://quote.eastmoney.com/unify/r/0.300832" class="em_stock_key_common" data-code="0,300832">新产业</span>链(CXO)方面：2022年及未来3-5年来看，CXO板块依旧是医药板块中景气度、持续性、长期逻辑最好的细分方向，核心驱动因素为：海外产业转移、产业升级、国内医药创新崛起等。CXO板块的成长性和确定性强，长期来看应当享受一定估值溢价，板块龙头公司估值已经进入底部区间，配置性价比高。市场情绪方面，持续开始回暖，我们预计随着3月份年报的陆续披露和一季度经营情况的更新，市场情绪将进一步回暖。</p><p>原料药板块方面：原料药板块在中间体与原料药、制剂及CDMO项目产能建设方面持续推进。在十四五医药工业发展规划对原料药持续支持的大背景下，相关企业业绩有望稳步提升，2022年盈利能力有望持续改善(2021年上游原材料涨价、汇率、运费上涨，利润率有所波动)。</p><p>继续看好上游供应链：重点看好十四五期间供应链方面的投资机遇(产业升级+国产替代)，包括装备设备、科学仪器、科研配套上游试剂耗材、医药工业上游耗材和原辅料包材等细分领域。投资建议来看，关注<span id="stock_1.603259"><a href="http://quote.eastmoney.com/unify/r/1.603259" class="keytip" data-code="1,603259">药明康德</a></span><span id="quote_1.603259"></span>、<span id="stock_1.603456"><a href="http://quote.eastmoney.com/unify/r/1.603456" class="keytip" data-code="1,603456">九洲药业</a></span><span id="quote_1.603456"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.002821" class="em_stock_key_common" data-code="0,002821">凯莱英</span>、<span id="stock_1.603229"><a href="http://quote.eastmoney.com/unify/r/1.603229" class="keytip" data-code="1,603229">奥翔药业</a></span><span id="quote_1.603229"></span>、<span id="stock_0.300203"><a href="http://quote.eastmoney.com/unify/r/0.300203" class="keytip" data-code="0,300203">聚光科技</a></span><span id="quote_0.300203"></span>等。<a href="https://dfscdn.dfcfw.com/download/A2_cms_f_20220225112500672819&direct=1&abc2353.pdf">【点击查看研报原文】</a></p><p><strong><span id="stock_1.601788"><a href="http://quote.eastmoney.com/unify/r/1.601788" class="keytip" data-code="1,601788">光大证券</a></span><span id="quote_1.601788"></span>：创新药利空因素出清 优质资产迎来布局良机</strong></p><p>创新药板块在过去一年中的整体表现不佳，我们估计导致创新药企业股价下跌的因素除了之前的高估值有回调压力之外，基本面也有相应的压制因素，比如医保谈判降价的风险、创新药出海失败的风险，都导致市场投资者对行业的发展出现一定担忧。随着创新药板块的估值压力释放、医保谈判和出海的利空因素出清，优质资产已经迎来布局良机，推荐<span id="Info.116.09995"><a href="http://quote.eastmoney.com/unify/r/116.09995" class="keytip" data-code="116,09995">荣昌生物-B</a></span>、<span id="Info.116.02162"><a href="http://quote.eastmoney.com/unify/r/116.02162" class="keytip" data-code="116,02162">康诺亚-B</a></span>，建议关注<span web="1" href="http://quote.eastmoney.com/unify/r/116.01877" class="em_stock_key_common" data-code="116,01877">君实生物</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/116.01801" class="em_stock_key_common" data-code="116,01801">信达生物</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.600276" class="em_stock_key_common" data-code="1,600276">恒瑞医药</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/116.06160" class="em_stock_key_common" data-code="116,06160">百济神州</span>等。</p><p>基于医药投资的变与不变，我们认为未来应当积极把握创新化和国际化方向的投资机会。创新药与疫苗方面，推荐<span web="1" href="http://quote.eastmoney.com/unify/r/116.01801" class="em_stock_key_common" data-code="116,01801">信达生物</span>(H)、荣昌生物(H)；CXO 方面，推荐<span id="Info.116.02269"><a href="http://quote.eastmoney.com/unify/r/116.02269" class="keytip" data-code="116,02269">药明生物</a></span>(H)、<span id="stock_0.300759"><a href="http://quote.eastmoney.com/unify/r/0.300759" class="keytip" data-code="0,300759">康龙化成</a></span><span id="quote_0.300759"></span>、<span id="stock_1.688131"><a href="http://quote.eastmoney.com/unify/r/1.688131" class="keytip" data-code="1,688131">皓元医药</a></span><span id="quote_1.688131"></span>、 <span web="1" href="http://quote.eastmoney.com/unify/r/0.300725" class="em_stock_key_common" data-code="0,300725">药石科技</span>；器械设备与生命科学领域，推荐<span web="1" href="http://quote.eastmoney.com/unify/r/0.300760" class="em_stock_key_common" data-code="0,300760">迈瑞医疗</span>、<span id="Info.116.00853"><a href="http://quote.eastmoney.com/unify/r/116.00853" class="keytip" data-code="116,00853">微创医疗</a></span>(H)、<span id="stock_1.600587"><a href="http://quote.eastmoney.com/unify/r/1.600587" class="keytip" data-code="1,600587">新华医疗</a></span><span id="quote_1.600587"></span>、<span id="stock_0.300685"><a href="http://quote.eastmoney.com/unify/r/0.300685" class="keytip" data-code="0,300685">艾德生物</a></span><span id="quote_0.300685"></span>、<span id="stock_1.688301"><a href="http://quote.eastmoney.com/unify/r/1.688301" class="keytip" data-code="1,688301">奕瑞科技</a></span><span id="quote_1.688301"></span>；创新前沿技术方面，关注艾博生物等未上市企业；内需消费方面，推荐<span id="Info.116.01951"><a href="http://quote.eastmoney.com/unify/r/116.01951" class="keytip" data-code="116,01951">锦欣生殖</a></span>(H)、<span id="stock_1.603883"><a href="http://quote.eastmoney.com/unify/r/1.603883" class="keytip" data-code="1,603883">老百姓</a></span><span id="quote_1.603883"></span>、<span id="stock_0.000915"><a href="http://quote.eastmoney.com/unify/r/0.000915" class="keytip" data-code="0,000915">华特达因</a></span><span id="quote_0.000915"></span>、<span id="stock_0.300294"><a href="http://quote.eastmoney.com/unify/r/0.300294" class="keytip" data-code="0,300294">博雅生物</a></span><span id="quote_0.300294"></span>。<a href="https://dfscdn.dfcfw.com/download/A2_cms_f_20220225112513469336&direct=1&abc5598.pdf">【点击查看研报原文】</a></p><p><strong><span id="stock_0.002736"><a href="http://quote.eastmoney.com/unify/r/0.002736" class="keytip" data-code="0,002736">国信证券</a></span><span id="quote_0.002736"></span>：医药生物板块具有较高性价比！关注景气赛道估值与增速匹配的优质标的</strong></p><p>在国内外宏观环境存在不确定性、冬季全球新冠疫情反复阶段，我们认为医药生物板块具有较高性价比，建议继续关注景气赛道估值与增速匹配的优质标的：<span web="1" href="http://quote.eastmoney.com/unify/r/1.600276" class="em_stock_key_common" data-code="1,600276">恒瑞医药</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300760" class="em_stock_key_common" data-code="0,300760">迈瑞医疗</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.603259" class="em_stock_key_common" data-code="1,603259">药明康德</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/116.02269" class="em_stock_key_common" data-code="116,02269">药明生物</span>、<span id="Info.116.01548"><a href="http://quote.eastmoney.com/unify/r/116.01548" class="keytip" data-code="116,01548">金斯瑞生物科技</a></span>、<span id="stock_1.600196"><a href="http://quote.eastmoney.com/unify/r/1.600196" class="keytip" data-code="1,600196">复星医药</a></span><span id="quote_1.600196"></span>、<span id="stock_0.000739"><a href="http://quote.eastmoney.com/unify/r/0.000739" class="keytip" data-code="0,000739">普洛药业</a></span><span id="quote_0.000739"></span>、康诺亚、<span web="1" href="http://quote.eastmoney.com/unify/r/106.GLW" class="em_stock_key_common" data-code="106,GLW">康宁</span>杰瑞制药等。</p><p>国内疫情点状散发呈常态化，序贯加强免疫落地将有助于进一步提升群体免疫屏障，国内本轮加强免疫预计即将过半，未来3~4个月预计仍有6~7亿人次序贯加强需求。丽珠单抗V-01、瑞科生物ReCov等产品仍在推动海外III期临床，未来有望进一步丰富国内新冠疫苗品种。全球疫情略有缓和但新增确诊病例等数据仍处于历史高位，新冠疫苗全球供应存在结构性失衡，目前国内2款新冠疫苗正在推进WHOEUL认证工作，未来有望进一步开拓海外市场。建议持续关注新冠疫苗相关标的：<span web="1" href="http://quote.eastmoney.com/unify/r/0.300122" class="em_stock_key_common" data-code="0,300122">智飞生物</span>、<span id="Info.116.06185"><a href="http://quote.eastmoney.com/unify/r/116.06185" class="keytip" data-code="116,06185">康希诺生物-B</a></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.600196" class="em_stock_key_common" data-code="1,600196">复星医药</span>等。<a href="https://dfscdn.dfcfw.com/download/A2_cms_f_20220225112526172871&direct=1&abc6357.pdf">【点击查看研报原文】</a></p><p><strong>国盛<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0473" class="em_stock_key_common" data-code="90,BK0473">证券</span>：医药已经进入中长期的布局区间 更重“业绩估值筹码”三因素</strong></p><p>医药已经进入中长期的布局区间，中短期仍然是自下而上，更重“业绩估值筹码”三因素。医药调整到现在，“双高问题”得到了一定消化，虽然有很多资产短期估值难言极度便宜且短期担忧难以证伪，但从中长期来看已经进入到了配置区间。而从中短期来看，其实没有系统性的解决方案，最近整个市场筹码结构又出现了问题，我们的思路仍然是自下而上去选择个股，总结下来有三点：1)选择具备“基本面常识性估值超跌折价”的个股，换句话说，就是跌到了非理性估值区间的二阶导。2)选择“内需政策免疫”、“外需偏刚性”细分领域，这个是考虑到当下地缘政治环境和医药政策环境的综合的豁然影响，尤其是情绪上的影响。如成人二类疫苗、自主可控、国内新冠治疗药产业链、中药、康复、CDMO 等。3)因阶段性交易混沌度高，抄底时要充分考虑筹码因素。<a href="https://dfscdn.dfcfw.com/download/A2_cms_f_20220225112538953561&direct=1&abc8215.pdf">【点击查看研报原文】</a></p><p><strong><span id="stock_1.600909"><a href="http://quote.eastmoney.com/unify/r/1.600909" class="keytip" data-code="1,600909">华安证券</a></span><span id="quote_1.600909"></span>：风物长宜放眼量！多数医药公司的估值都已经到了非常合理的区间</strong></p><p>考虑到的医药行业的背景，一方面，今年集采政策持续推进落地(耗材集采、国采、联盟采等)带来的不确定性，另外，短期医药行业板块暂没看到明确的利好政策/变化，短期无上涨动力。风物长宜放眼量，很多医药公司的估值都已经到了非常合理的区间，政策带来的变动不确定性让很多投资者无从下手。我们建议今年全年的方向配置：中药(政策友好+低估值)+医疗设备(医疗基建)+科研试剂和上游等+其他方向自下而上寻找标的。</p><p>(1)中药板块：品牌名贵OTC+中药创新药+中医连锁，我们推荐：<span id="stock_0.002873"><a href="http://quote.eastmoney.com/unify/r/0.002873" class="keytip" data-code="0,002873">新天药业</a></span><span id="quote_0.002873"></span>、<span id="stock_1.603439"><a href="http://quote.eastmoney.com/unify/r/1.603439" class="keytip" data-code="1,603439">贵州三力</a></span><span id="quote_1.603439"></span>、<span id="stock_0.000999"><a href="http://quote.eastmoney.com/unify/r/0.000999" class="keytip" data-code="0,000999">华润三九</a></span><span id="quote_0.000999"></span>、<span id="stock_1.600976"><a href="http://quote.eastmoney.com/unify/r/1.600976" class="keytip" data-code="1,600976">健民集团</a></span><span id="quote_1.600976"></span>、<span id="Info.116.02273"><a href="http://quote.eastmoney.com/unify/r/116.02273" class="keytip" data-code="116,02273">固生堂</a></span>等标的，也推荐关注：<span id="stock_1.600085"><a href="http://quote.eastmoney.com/unify/r/1.600085" class="keytip" data-code="1,600085">同仁堂</a></span><span id="quote_1.600085"></span>、<span id="stock_0.002603"><a href="http://quote.eastmoney.com/unify/r/0.002603" class="keytip" data-code="0,002603">以岭药业</a></span><span id="quote_0.002603"></span>、<span id="stock_1.600557"><a href="http://quote.eastmoney.com/unify/r/1.600557" class="keytip" data-code="1,600557">康缘药业</a></span><span id="quote_1.600557"></span>、<span id="stock_1.600535"><a href="http://quote.eastmoney.com/unify/r/1.600535" class="keytip" data-code="1,600535">天士力</a></span><span id="quote_1.600535"></span>、<span id="stock_1.603998"><a href="http://quote.eastmoney.com/unify/r/1.603998" class="keytip" data-code="1,603998">方盛制药</a></span><span id="quote_1.603998"></span>、<span id="stock_0.002728"><a href="http://quote.eastmoney.com/unify/r/0.002728" class="keytip" data-code="0,002728">特一药业</a></span><span id="quote_0.002728"></span>、<span id="stock_0.002275"><a href="http://quote.eastmoney.com/unify/r/0.002275" class="keytip" data-code="0,002275">桂林三金</a></span><span id="quote_0.002275"></span>、<span id="stock_1.603896"><a href="http://quote.eastmoney.com/unify/r/1.603896" class="keytip" data-code="1,603896">寿仙谷</a></span><span id="quote_1.603896"></span>等标的。</p><p>(2)医疗设备板块：我们推荐关注迈瑞医疗、<span id="stock_0.300633"><a href="http://quote.eastmoney.com/unify/r/0.300633" class="keytip" data-code="0,300633">开立医疗</a></span><span id="quote_0.300633"></span>、<span id="stock_0.300206"><a href="http://quote.eastmoney.com/unify/r/0.300206" class="keytip" data-code="0,300206">理邦仪器</a></span><span id="quote_0.300206"></span>、<span id="stock_0.002223"><a href="http://quote.eastmoney.com/unify/r/0.002223" class="keytip" data-code="0,002223">鱼跃医疗</a></span><span id="quote_0.002223"></span>、<span id="stock_1.688626"><a href="http://quote.eastmoney.com/unify/r/1.688626" class="keytip" data-code="1,688626">翔宇医疗</a></span><span id="quote_1.688626"></span>、<span id="stock_1.688580"><a href="http://quote.eastmoney.com/unify/r/1.688580" class="keytip" data-code="1,688580">伟思医疗</a></span><span id="quote_1.688580"></span>、<span id="stock_0.300453"><a href="http://quote.eastmoney.com/unify/r/0.300453" class="keytip" data-code="0,300453">三鑫医疗</a></span><span id="quote_0.300453"></span>等，此外，IVD板块其实也会受益于医疗基建，推荐关注<span web="1" href="http://quote.eastmoney.com/unify/r/0.300832" class="em_stock_key_common" data-code="0,300832">新产业</span>、<span id="stock_1.688575"><a href="http://quote.eastmoney.com/unify/r/1.688575" class="keytip" data-code="1,688575">亚辉龙</a></span><span id="quote_1.688575"></span>、<span id="stock_1.603658"><a href="http://quote.eastmoney.com/unify/r/1.603658" class="keytip" data-code="1,603658">安图生物</a></span><span id="quote_1.603658"></span>、<span id="stock_1.688389"><a href="http://quote.eastmoney.com/unify/r/1.688389" class="keytip" data-code="1,688389">普门科技</a></span><span id="quote_1.688389"></span>、<span id="stock_0.300463"><a href="http://quote.eastmoney.com/unify/r/0.300463" class="keytip" data-code="0,300463">迈克生物</a></span><span id="quote_0.300463"></span>、<span id="stock_0.300642"><a href="http://quote.eastmoney.com/unify/r/0.300642" class="keytip" data-code="0,300642">透景生命</a></span><span id="quote_0.300642"></span>、<span id="stock_0.300482"><a href="http://quote.eastmoney.com/unify/r/0.300482" class="keytip" data-code="0,300482">万孚生物</a></span><span id="quote_0.300482"></span>等。</p><p>(3)科研试剂和上游等：我们提议关注<span id="stock_1.688105"><a href="http://quote.eastmoney.com/unify/r/1.688105" class="keytip" data-code="1,688105">诺唯赞</a></span><span id="quote_1.688105"></span>、<span id="stock_1.688690"><a href="http://quote.eastmoney.com/unify/r/1.688690" class="keytip" data-code="1,688690">纳微科技</a></span><span id="quote_1.688690"></span>、<span id="stock_0.301080"><a href="http://quote.eastmoney.com/unify/r/0.301080" class="keytip" data-code="0,301080">百普赛斯</a></span><span id="quote_0.301080"></span>、<span id="stock_1.688133"><a href="http://quote.eastmoney.com/unify/r/1.688133" class="keytip" data-code="1,688133">泰坦科技</a></span><span id="quote_1.688133"></span>、<span id="stock_1.688179"><a href="http://quote.eastmoney.com/unify/r/1.688179" class="keytip" data-code="1,688179">阿拉丁</a></span><span id="quote_1.688179"></span>、<span id="stock_1.688026"><a href="http://quote.eastmoney.com/unify/r/1.688026" class="keytip" data-code="1,688026">洁特生物</a></span><span id="quote_1.688026"></span>、<span id="stock_0.300171"><a href="http://quote.eastmoney.com/unify/r/0.300171" class="keytip" data-code="0,300171">东富龙</a></span><span id="quote_0.300171"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300203" class="em_stock_key_common" data-code="0,300203">聚光科技</span>、<span id="stock_0.300358"><a href="http://quote.eastmoney.com/unify/r/0.300358" class="keytip" data-code="0,300358">楚天科技</a></span><span id="quote_0.300358"></span>、<span id="stock_0.300813"><a href="http://quote.eastmoney.com/unify/r/0.300813" class="keytip" data-code="0,300813">泰林生物</a></span><span id="quote_0.300813"></span>等。</p><p>(4)其他自下而上的板块和公司，需要根据行业和公司的标的和估值去做分析，提议关注：再生医学板块的<span web="1" href="http://quote.eastmoney.com/unify/r/0.300653" class="em_stock_key_common" data-code="0,300653">正海生物</span>、<span id="stock_0.301033"><a href="http://quote.eastmoney.com/unify/r/0.301033" class="keytip" data-code="0,301033">迈普医学</a></span><span id="quote_0.301033"></span>等标的；<span id="bk_90.BK0727"><a href="http://quote.eastmoney.com/unify/r/90.BK0727" class="keytip" data-code="90,BK0727">医疗服务</a></span><span id="bkquote_90.BK0727"></span>板块估值低，我们推荐具备性价比和扩张性强的海吉亚和<span web="1" href="http://quote.eastmoney.com/unify/r/116.02273" class="em_stock_key_common" data-code="116,02273">固生堂</span>，建议关注<span web="1" href="http://quote.eastmoney.com/unify/r/0.300015" class="em_stock_key_common" data-code="0,300015">爱尔眼科</span>、<span id="Info.116.02219"><a href="http://quote.eastmoney.com/unify/r/116.02219" class="keytip" data-code="116,02219">朝聚眼科</a></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/116.01951" class="em_stock_key_common" data-code="116,01951">锦欣生殖</span>等；<span id="bk_90.BK1044"><a href="http://quote.eastmoney.com/unify/r/90.BK1044" class="keytip" data-code="90,BK1044">生物制品</a></span><span id="bkquote_90.BK1044"></span>，疫苗板块需要持续关注，我们推荐<span web="1" href="http://quote.eastmoney.com/unify/r/0.300122" class="em_stock_key_common" data-code="0,300122">智飞生物</span>、<span id="stock_1.688276"><a href="http://quote.eastmoney.com/unify/r/1.688276" class="keytip" data-code="1,688276">百克生物</a></span><span id="quote_1.688276"></span>，建议关注<span web="1" href="http://quote.eastmoney.com/unify/r/0.300142" class="em_stock_key_common" data-code="0,300142">沃森生物</span>、康希诺、<span id="stock_1.688319"><a href="http://quote.eastmoney.com/unify/r/1.688319" class="keytip" data-code="1,688319">欧林生物</a></span><span id="quote_1.688319"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.603392" class="em_stock_key_common" data-code="1,603392">万泰生物</span>等；家用<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1041" class="em_stock_key_common" data-code="90,BK1041">医疗器械</span>，建议关注<span web="1" href="http://quote.eastmoney.com/unify/r/0.002223" class="em_stock_key_common" data-code="0,002223">鱼跃医疗</span>、<span id="stock_0.301087"><a href="http://quote.eastmoney.com/unify/r/0.301087" class="keytip" data-code="0,301087">可孚医疗</a></span><span id="quote_0.301087"></span>。</p><p>(5)此外，创新药板块，建议关注具备国际化能力的创新药标的，我们建议关注恒瑞医药、<span web="1" href="http://quote.eastmoney.com/unify/r/116.06160" class="em_stock_key_common" data-code="116,06160">百济神州</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/116.01877" class="em_stock_key_common" data-code="116,01877">君实生物</span>、<span id="stock_0.300558"><a href="http://quote.eastmoney.com/unify/r/0.300558" class="keytip" data-code="0,300558">贝达药业</a></span><span id="quote_0.300558"></span>、<span id="Info.116.00013"><a href="http://quote.eastmoney.com/unify/r/116.00013" class="keytip" data-code="116,00013">和黄医药</a></span>、康方生物、<span id="Info.116.01177"><a href="http://quote.eastmoney.com/unify/r/116.01177" class="keytip" data-code="116,01177">中国生物制药</a></span>等。<a href="https://dfscdn.dfcfw.com/download/A2_cms_f_20220225112550047870&direct=1&abc988.pdf">【点击查看研报原文】</a></p><p class="em_media">（文章来源：<span web="1" href="http://quote.eastmoney.com/unify/r/0.300059" class="em_stock_key_common" data-code="0,300059">东方财富</span>研究中心）</p>

<http://stock.eastmoney.com/news/1405,202202252289188775.html>

[返回东财滚动新闻](//finews.withounder.com/emnews/)｜[返回首页](//finews.withounder.com/)